ALERT: Rosen Law Firm Reminds Ply Gem Holdings Investors of

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
ALERT: Rosen Law Firm Reminds Ply Gem Holdings Investors of Important July 18, 2014 Class Action Deadline - PGEM

NEW YORK, July 7, 2014 (GLOBE NEWSWIRE) -- The Rosen Law Firm, P.A. reminds purchasers of Ply Gem Holdings, Inc. stock (NYSE: PGEM ) of the important July 18, 2014 lead plaintiff deadline.

To join the PGEM class action, visit the firm's website at http://rosenlegal.com , or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free, at 866-767-3653; you may also email pkim@rosenlegal.com or kchan@rosenlegal.com for information on the class action. The lawsuit is pending in the U.S. District Court for the Southern District of New York

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY CHOOSE TO DO NOTHING AT THIS POINT AND REMAIN AN ABSENT CLASS MEMBER.

On or about May 22, 2013, the SEC declared effective Ply Gem's Form S-1 Registration Statement, and Ply Gem conducted its Initial Public Offering ("IPO"). The complaint alleges that the Registration Statement, failed to disclose negative material trends and events. These material events included: (i) that Ply Gem had agreed to buy back certain inventory from The Home Depot, Inc. as an accommodation related to a new supply agreement between the two companies, and initially to sell it lower-priced, lower-margin product; (ii) that April 2013 was a particularly poor month for the Company, with management noting that "maybe it wasn't our worst April in eight years, but it was our worst in a while"; and (iii) that high customer inventory at the end of the first quarter was adversely affecting the demand for and sales of Ply Gem's siding products in April 2013 and May 2013.

If you wish to serve as lead plaintiff, you must move the Court no later than July 18, 2014. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of The Rosen Law Firm, toll-free, at 866-767-3653, or via e-mail at pkim@rosenlegal.com . You may also visit the firm's website at http://rosenlegal.com .

The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.

Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm P.A. 275 Madison Avenue, 34th Floor New York, New York 10016 Tel: (212) 686-1060 Toll Free: 1-866-767-3653 Fax: (212) 202-3827 www.rosenlegal.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 378

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 340

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 63

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 247

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 505

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 262

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 425

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 48

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
PASCAL's Holiday Gift Edit: Timeless Watches Shine

Updated Category News Views 456

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 468

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading

Top 5 Most Recently Viewed Articles

C3is Inc (CISS) Hits 52-Week Low; Analyzing Market Challenges

Updated Category News Views 210

C3is Inc (CISS) hit a new low recently, dropping to $1.09 a share. This marks a staggering 97.53% decline over the past year, leaving investors scratching their heads about where this company is headed next. C3is Inc: A Company in Crisis As the stock tumbles to its 52-week low, the implications for C3is's market position are glaring. With a market cap of just $6.75...

Continue Reading
Securitas AB Set to Release Q3 2025 Financial Results Soon

Updated Category News Views 308

Securitas AB Announces Release of Q3 2025 Results STOCKHOLM, Oct. 29, 2025 - Securitas AB is gearing up to publish its Interim Report for the period of January to September 2025 on Thursday, November 6, 2025, at 8:00 a.m. CET. This important financial document will provide insights into the company's performance and outlook for the future. Details of the Report Release...

Continue Reading
XRP Whales Drive Demand for ExoraPad's $EXP as Presale Surges

Updated Category News Views 216

XRP Whales Drive Demand for ExoraPad's $EXP as Presale Surges In a remarkable show of confidence, XRP whales are actively positioning themselves to acquire ExoraPad's $EXP tokens, resulting in a presale that has quickly exceeded expectations. This impressive feat has occurred just hours after the presale launch, where over 30% of the softcap has already been raised,...

Continue Reading
Innovative Partnership for Elderly Services and Board Changes

Updated Category News Views 164

Strengthening Services for the Elderly CLIK is thrilled to announce its exciting new partnership with Flash Mutual, a cutting-edge technology firm operating under Tencent's Sustainable Social Value initiatives. This collaboration is designed to deliver round-the-clock instant device services specifically aimed at enhancing the lives of senior citizens. A Focus on...

Continue Reading
Microsoft's Fourth-Quarter Forecast: Anticipating Growth and Innovation

Updated Category News Views 217

Overview of Microsoft's Upcoming Fourth Quarter Earnings Microsoft Corporation (NASDAQ: MSFT) is positioning itself for a robust financial report as it gears up to share its fourth-quarter results. Analysts are excited about the anticipated growth driven by advancements in AI and cloud services, highlighting the company's impressive trajectory in the tech sphere. Earnings...

Continue Reading